PMID- 36881639
OWN - NLM
STAT- MEDLINE
DCOM- 20230707
LR  - 20230718
IS  - 1943-7722 (Electronic)
IS  - 0002-9173 (Linking)
VI  - 160
IP  - 1
DP  - 2023 Jul 5
TI  - Integrated Genomic DNA/RNA Profiling vs Fluorescence in Situ Hybridization in the 
      Detection of MYC and BCL2 (and BCL6) Rearrangements in Large B-Cell Lymphomas: 
      Updates Amid the New WHO Classification of Lymphoid Neoplasms.
PG  - 41-48
LID - 10.1093/ajcp/aqad006 [doi]
AB  - OBJECTIVES: Large B-cell lymphomas (LBCLs) are a heterogeneous group of lymphoid 
      neoplasms whose molecular and cytogenetic profile has predictive and prognostic 
      implications. The concept of double-hit lymphomas (DHLs) was recently updated in 
      the fifth edition of the World Health Organization classification, with the 
      exclusion of MYC and BCL6 rearranged tumors from the group. Now, DHLs are 
      referred to as diffuse large B-cell lymphoma/high-grade B-cell lymphoma with MYC 
      and BCL2 rearrangements. Fluorescence in situ hybridization (FISH) is the current 
      gold standard for detecting rearrangements in LBCLs, but comprehensive genomic 
      profiling (CGP) has recently been suggested to be at least as accurate as FISH in 
      classifying these neoplasms and providing additional genetic information. 
      METHODS: We analyzed a cohort of 131 patients in whom FISH and CGP studies were 
      performed as part of our normal clinical workflow and compared the effectiveness 
      of FISH and CGP in detecting these clinically relevant rearrangements. RESULTS: 
      Our findings are in agreement with our previously published study, which analyzed 
      a cohort of 69 patients, supporting our hypothesis that the best approach to 
      maximize detection of DHLs while limiting waste seems to be a combination of CGP 
      and MYC break-apart FISH testing, the latter to capture the presence of 
      non-IGH::MYC events. CONCLUSIONS: Our study supports the combined use of FISH and 
      GCP rather than either method alone to better detect MYC and BCL2 (and BCL6) gene 
      rearrangements.
CI  - (c) The Author(s) 2023. Published by Oxford University Press on behalf of American 
      Society for Clinical Pathology. All rights reserved. For permissions, please 
      e-mail: journals.permissions@oup.com.
FAU - de Lima Guido, Luiz Paulo
AU  - de Lima Guido LP
AUID- ORCID: 0000-0003-2067-9754
AD  - Department of Pathology, Jackson Memorial Hospital, Miami, FL, US.
AD  - Department of Pathology and Laboratory Medicine, University of Miami, Miami, FL, 
      US.
FAU - Chapman, Jennifer
AU  - Chapman J
AD  - Department of Pathology and Laboratory Medicine, University of Miami, Miami, FL, 
      US.
FAU - Cassidy, Daniel P
AU  - Cassidy DP
AD  - Department of Pathology and Laboratory Medicine, University of Miami, Miami, FL, 
      US.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Am J Clin Pathol
JT  - American journal of clinical pathology
JID - 0370470
RN  - 0 (Proto-Oncogene Proteins c-bcl-6)
RN  - 0 (Proto-Oncogene Proteins c-myc)
RN  - 0 (Proto-Oncogene Proteins c-bcl-2)
RN  - 0 (BCL6 protein, human)
RN  - 0 (BCL2 protein, human)
SB  - IM
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Proto-Oncogene Proteins c-bcl-6/genetics
MH  - *Proto-Oncogene Proteins c-myc/genetics
MH  - Proto-Oncogene Proteins c-bcl-2/genetics
MH  - *Lymphoma, Large B-Cell, Diffuse/diagnosis/genetics/pathology
MH  - Gene Rearrangement
MH  - Genomics
OTO - NOTNLM
OT  - Comprehensive genomic profiling
OT  - Diffuse large B-cell lymphoma
OT  - Double-hit lymphoma
OT  - Fluorescence in situ hybridization
OT  - High-grade B-cell lymphoma
OT  - Large B-cell lymphoma
EDAT- 2023/03/08 06:00
MHDA- 2023/07/07 06:42
CRDT- 2023/03/07 14:05
PHST- 2022/10/04 00:00 [received]
PHST- 2023/01/16 00:00 [accepted]
PHST- 2023/07/07 06:42 [medline]
PHST- 2023/03/08 06:00 [pubmed]
PHST- 2023/03/07 14:05 [entrez]
AID - 7070531 [pii]
AID - 10.1093/ajcp/aqad006 [doi]
PST - ppublish
SO  - Am J Clin Pathol. 2023 Jul 5;160(1):41-48. doi: 10.1093/ajcp/aqad006.